This site is intended for health professionals only
Monday 22 October 2018
Share |

Topic: Research

September 26, 2018
My role as a clinical education research pharmacist

Clinical education research pharmacist Michael Lloyd shares his pharmacy journey
 
Undergraduate experiences developed an interest in quantitative research, with my early career seeing involvement in many audits and quality improvement projects. I later completed a postgraduate Master’s degree that illuminated the world of qualitative methodologies and I was hooked!
 

September 26, 2018
My role as a clinical education research pharmacist

Clinical education research pharmacist Michael Lloyd shares his pharmacy journey
 
Undergraduate experiences developed an interest in quantitative research, with my early career seeing involvement in many audits and quality improvement projects. I later completed a postgraduate Master’s degree that illuminated the world of qualitative methodologies and I was hooked!
 

June 27, 2018
Oral Semaglutide demonstrates significant reduction in blood sugar versus placebo in trial

A once-daily tablet could reduce blood sugar in adults with type 2 diabetes, a study has shown.
 
Oral semaglutide, an investigational GLP-1 analogue from global healthcare company Novo Nordisk,achieved “significant reductions in blood sugar versus placebo in adults with type 2 diabetes”, according to the PIONEER 1 phase 3a trial.
 
The trial evaluated the efficacy and safety of 3, 7 and 14 mg oral semaglutide compared with placebo as monotherapy over 26 weeks in adults with type 2 diabetes. [1] 
 

June 25, 2018
Stephanie Annett has a PhD in experimental therapeutics, is a researcher for novel immunotherapies and a lecturer of pharmacology at the Royal College of Surgeons Ireland and locums in community pharmacy

Stephanie Annett has a PhD in experimental therapeutics, is a researcher for novel immunotherapies and a lecturer of pharmacology at the Royal College of Surgeons Ireland and locums in community pharmacy.
 
She talks to Léa Legraien about her passion for research and pharmacy and her success.
 
 
Q Why did you become a pharmacist?
 
I was always interested in science, which I had chosen at A-level.
 

June 25, 2018
Stephanie Annett has a PhD in experimental therapeutics, is a researcher for novel immunotherapies and a lecturer of pharmacology at the Royal College of Surgeons Ireland and locums in community pharmacy

Stephanie Annett has a PhD in experimental therapeutics, is a researcher for novel immunotherapies and a lecturer of pharmacology at the Royal College of Surgeons Ireland and locums in community pharmacy.
 
She talks to Léa Legraien about her passion for research and pharmacy and her success.
 
 
Q Why did you become a pharmacist?
 
I was always interested in science, which I had chosen at A-level.
 

June 21, 2018
Targeted therapy to block a protein that suppresses T cell activity could improve cancer treatment with immune checkpoint inhibitors

A targeted therapy to block a protein that suppresses T cell activity could improve cancer treatment with immune checkpoint inhibitors, researchers have found.
 
EZH2 is elevated in immune T cells in patients after treatment with ipilimumab, a team at the University of Texas MD Anderson Cancer Center showed. The drug unleashes an immune response by blocking the activity of CTLA-4 on T cells – white blood cells that serve as the ‘targeted warriors’ of the adaptive immune system.
 

June 20, 2018
Idorsia launches PRECISION – Phase 3 study with aprocitentan for resistant hypertension management in adults

Swiss biopharmaceuticals business Idorsia has announced that the first patient has been enrolled into PRECISION, a Phase 3 study to investigate the efficacy and safety of aprocitentan for managing resistant hypertension in adults [June 20 2018].
 

May 3, 2018
Leading cancer charities launch awards to help advance understanding of the disease and develop new treatments to improve survival

Leading cancer charities have established a multi million pound fund to improve the understanding and treatment of brain tumours.

 

The Cancer Research UK Brain Tumour Awards was launched this month [1 May] by Cancer Research UK in partnership with The Brain Tumour Charity to help advance understanding about the biology of the disease and the challenges translating discoveries into treatments.

 

April 12, 2018
Gene discovery could lead to future individualised therapy in myeloma, researchers find

Researchers have increased the understanding of the complex genetics behind an incurable blood cancer.

 

The Institute of Cancer Research, London, has conducted a study which has revealed 40 genes involved in the development of myeloma, enhancing the knowledge about the complex genetics associated with this condition.

 

April 6, 2018
<p>UK Biobank has announced a major initiative to sequence the full genomes of 50,000 UK Biobank volunteer participants</p>

Funded by a £30M grant from the Medical Research Council (MRC), sequencing of the whole genome will be undertaken during 2018 and 2019 by the Wellcome Sanger Institute, which is based in Cambridge.

 

February 9, 2018
Pharmacists have a vital role in early identification and reconciliation of medications in PD patients and this has the potential to prevent deterioration and prevent further morbidity in this patient profile.

Abstract

Introduction Parkinson's disease (PD) is a high-risk chronic condition putting patients at risk of a number of potential complications if not managed appropriately. Emergency departments (EDs) are often ill-equipped to reconcile and continue vital medications for PD, and dramatic deterioration in symptoms and increased morbidity may occur as a result. The role of pharmacists in early reconciliation in this high-risk patient group is not fully explored in the current literature. 

 

February 8, 2018
Doctors have developed a new five-minute procedure to scan the blood vessels which offers hope for claustrophobic patients unable to tolerate the conventional longer test

Magnetic resonance angiography (MRA) is a magnetic resonance imaging (MRI) exam that takes pictures of the blood vessels. Physicians use the images to diagnose diseases of the blood vessels, such as aneurysms or blockages.
 

December 12, 2017
Globally, 694,000 people die from bowel cancer and 1.4 million people are diagnosed every year

Almost 332,000 people living in the UK will needlessly lose their lives to bowel cancer – a preventable, treatable and curable disease – between now and 2035 unless urgent action is taken to fill critical research gaps identified in a Bowel Cancer UK report ‘Finding the Key to the Cures: a plan to end bowel cancer by 2050’ launched today. If ignored, the scale of the issue will only grow larger.


The research has been published in the leading international academic journal, Gut.

December 1, 2017
Combining two different immunotherapy treatments could dramatically improve lymphoma survival, according to a Cancer Research UK funded study published in Cancer Cell

Researchers from the University of Southampton have tested different combinations of antibodies in the lab to see how they interact with each other and what effect this has on how the immune system fights cancer.


They found one combination – anti-CD27 and anti-CD20 – greatly increased life expectancy in mice with cancer. While most of the mice given just one of the antibodies died within 80 days, nearly all mice given both antibodies survived beyond 100 days.

May 18, 2016
Efficacy and tolerability were maintained in patients who switched from reference infliximab to biosimilar infliximab over the duration of the study with the results showing comparability to those patients who continued treatment on biosimilar infliximab

Long term data from the pivotal phase III PLANETRA study over 102 weeks demonstrating the clinical efficacy and safety profile of biosimilar infliximab in RA patients, has been published in Annals of the Rheumatic Diseases this month.1

May 17, 2016
A1M Pharma has initiated a research collaboration with global biotherapeutics company CSL Behring to investigate the potential of combining Alpha 1 Microglobulin (A1M) with proteins extracted from the fractionation of human plasma such as hemopexin and haptoglobin

A1M Pharma has initiated a research collaboration with global biotherapeutics company CSL Behring to investigate the potential of combining Alpha 1 Microglobulin (A1M) with proteins extracted from the fractionation of human plasma such as hemopexin and haptoglobin. This collaboration strengthens A1M Pharma’s position in the use of A1M for the treatment of life-threatening diseases with therapies that are based on naturally occurring substances.
 

May 17, 2016
A1M Pharma has initiated a research collaboration with global biotherapeutics company CSL Behring to investigate the potential of combining Alpha 1 Microglobulin (A1M) with proteins extracted from the fractionation of human plasma such as hemopexin and haptoglobin

A1M Pharma has initiated a research collaboration with global biotherapeutics company CSL Behring to investigate the potential of combining Alpha 1 Microglobulin (A1M) with proteins extracted from the fractionation of human plasma such as hemopexin and haptoglobin. This collaboration strengthens A1M Pharma’s position in the use of A1M for the treatment of life-threatening diseases with therapies that are based on naturally occurring substances.
 

March 22, 2016
Ten independent studies validate the growing bank of real-life clinical evidence to support switching patients from the reference infliximab (Remicade®) to biosimilar infliximab

March 9, 2016
Cosentyx launched as first-line systemic indication for psoriasis in UK in 2015 and recently approved for psoriatic arthritis and ankylosing spondylitis in Europe

Novartis announced new late-breaking data from the head-to-head CLEAR study, demonstrating that Cosentyx (secukinumab) remains superior to Stelara (ustekinumab) in achieving sustained skin clearance (PASI 90 response) at 52 weeks for adults living with moderate-to-severe psoriasis. These findings were presented for the first time at the American Academy of Dermatology (AAD) Annual Meeting in Washington, DC.1

 

March 8, 2016
Universities of Dundee (Scotland), & Cape Town (South Africa) partnering with Bayer (Germany)

World-leading medicinal chemistry and biology at the Universities of Dundee (Scotland) and Cape Town (South Africa) have been allied to the industrial expertise of the Pharmaceuticals Division of Bayer (Germany), one of the world’s leading pharma companies, in an effort to develop critically needed new treatments for tuberculosis (TB).
 

March 3, 2016
Study will evaluate efficacy, safety and immunogenicity of adalimumab biosimilar candidate MSB11022 compared with Humira®

Merck, a leading science and technology company, announced the initiation of a global Phase III clinical study of MSB11022, a proposed biosimilar of adalimumab, in chronic plaque psoriasis. This milestone is a strong reflection of Merck’s progress in biosimilars, with the goal of delivering high-quality biologics to patients all over the world.
 

March 2, 2016
Vaccine activates body’s own immune system to fight cancer

A new vaccine aimed at enabling the immune system to fight against advanced cancer is being trialled in London and Guildford.
 

Scientists are testing the effectiveness and safety of the vaccine, which works by resembling the natural immune responses generated by the body against bacterial and viral infections.
 

All patients with any solid tumour, irrespective of their type of cancer and tumour genetic profile, are believed to have the potential to benefit from this sort of treatment.
 

February 16, 2016
In a clinical trial, relapsed patients treated with carfilzomib in combination with lenalidomide and dexamethasone lived 8.7 months longer without disease progression compared with lenalidomide and dexamethasone alone

Amgen announced that Kyprolis® (carfilzomib) in combination with lenalidomide and dexamethasone is now available in the UK for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. Carfilzomib is the first licensed irreversible proteasome inhibitor for use in combination treatment of patients with relapsed multiple myeloma.1
 

 

January 25, 2016
First Phase III Vectibix trial to include a prespecified analysis of efficacy endpoints by RAS tumour status in primary analysis. Results presented at Gastrointestinal Cancers Symposium 2016 reinforce importance of RAS testing

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine